Palatin Technologies, Inc. (PTN)
Nasdaq · Healthcare · Biotechnology
$9.48+1.61%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $16.9M
- 52-week range
- $5.61 – $31.00
- 52-week change
- +28.34%
- EPS (trailing)
- −$2.96
- Analyst rating
- 1.3 Strong buy
Fiscal year to Jun 2026
- Revenue
- $8.8M
- Net income
- −$8.4M
- Operating margin
- −98.2%
- Diluted EPS
- −$2.96
- Free cash flow
- −$13.6M
From the company’s annual report on SEC EDGAR.
About Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Headquarters: Monmouth Junction, United States · 25 employees · palatin.com